ArticleAnnals of surgical oncology2022
Impact of Neoadjuvant Chemotherapy on Image-Defined Risk Factors in High-Risk Neuroblastoma.
Article in Annals of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Radiographic overestimation of inferior vena cava involvement in pediatric neuroblastoma: a case report.Journal of surgical case reports · 2026Article
- Image defined risk factor(s) and outcomes for abdominal neuroblastoma: a surgical perspective from a Thailand National Cancer Centre.Pediatric surgery international · 2026Article
- Advances in multi-omics research on neuroblastoma.Frontiers in pediatrics · 2026Review
- Vascular encasement image defined risk factors independently predict surgical complications in neuroblastoma.ANZ journal of surgery · 2025Article
- Quantitative MRI in Childhood Neuroblastoma: Beyond the Assessment of Image-defined Risk Factors.Radiology. Imaging cancer · 2024Review
- Image-defined risk factors associated with MYCN oncogene amplification in neuroblastoma and their association with overall survival.Abdominal radiology (New York) · 2024Article
- Association of image-defined risk factors with clinical features, tumor biology, and outcomes in neuroblastoma: a single-center retrospective study.European journal of pediatrics · 2023Article
- Contrast-enhanced computed tomography radiomics in predicting primary site response to neoadjuvant chemotherapy in high-risk neuroblastoma.Abdominal radiology (New York) · 2023Article
- High-Risk Neuroblastoma: A Surgical Perspective.Children (Basel, Switzerland) · 2023Review
- The Use of Cavitron Ultrasonic Surgical Aspirator for High-Risk Neuroblastoma with Image-Defined Risk Factors in Children.Children (Basel, Switzerland) · 2023Article
- Correlation between image-defined risk factors and surgical complications in patients with neuroblastoma: a retrospective study.Pediatric surgery international · 2023Article
- Letter to the Editor: Reflections on "Impact of Neoadjuvant Chemotherapy on Image-Defined Risk Factors in High-Risk Neuroblastoma".Annals of surgical oncology · 2022Article
- Changes in image-defined risk factors with neoadjuvant chemotherapy in pediatric abdominal neuroblastoma.Abdominal radiology (New York) · 2022Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
purposeImage-defined risk factors (IDRFs) are associated with surgical risks in neuroblastoma. We sought to evaluate the impact of neoadjuvant therapy on IDRFs and associated ability to achieve gross total resection (GTR) of locoregional disease in patients with high-risk neuroblastoma.
methodsWe retrospectively reviewed charts of patients treated on four consecutive high-risk neuroblastoma protocols over a 20-year period at a single institution. The number of IDRFs at diagnosis and just prior to surgery, and the percent decrease of tumor volume from just prior to surgery to the end of induction were determined.
resultsEighty-eight patients were included. There were 438 IDRFs (average 5.0 ± 3.1 per patient) at diagnosis and 198 (average 2.3 ± 1.9 per patient) after neoadjuvant chemotherapy (p < 0.01). A reduction in IDRFs was seen in 81.8% of patients with average decrease of 2.9 ± 2.5 per patient. The average percent reduction in tumor volume was 89.8 ± 18.9% and correlated with the number of IDRFs present after chemotherapy (p < 0.01). Three or fewer IDRFs prior to surgery was associated with the highest odds ratio for > 90% GTR at 9.33 [95% confidence interval 3.14-31.5].
conclusionNeoadjuvant chemotherapy reduced the number of IDRFs in the majority of patients with high-risk neuroblastoma. The number of IDRFs present after neoadjuvant therapy correlated with the extent of resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.